UY35288A - Piridonamidas como moduladores de canales de sodio - Google Patents

Piridonamidas como moduladores de canales de sodio

Info

Publication number
UY35288A
UY35288A UY0001035288A UY35288A UY35288A UY 35288 A UY35288 A UY 35288A UY 0001035288 A UY0001035288 A UY 0001035288A UY 35288 A UY35288 A UY 35288A UY 35288 A UY35288 A UY 35288A
Authority
UY
Uruguay
Prior art keywords
sodium channel
pyridonamids
channel modulators
compounds
pharmaceutically acceptable
Prior art date
Application number
UY0001035288A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Anderson Corey
Arumugam Vijayalaskmi
Iuliana Luci Asgian
Brian Richard Bear
Andreas P Termin
James Philip Johnson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UY35288A publication Critical patent/UY35288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención se refiere a compuestos de piridonamida de la fórmula I y I' o sus sales farmacéuticam ente aceptables, de utilidad como inhibidores de los canales de sodio La invención también proporci ona composiciones farmacéuticamente aceptables qu e comprenden los compuestos de la invención y métodos de uso de las composiciones en el tratamiento de diversos trastornos, incluyendo dolor.
UY0001035288A 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio UY35288A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
UY35288A true UY35288A (es) 2014-08-29

Family

ID=50073531

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035288A UY35288A (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio

Country Status (34)

Country Link
US (6) US9051270B2 (es)
EP (3) EP2953931B1 (es)
JP (4) JP6389194B2 (es)
KR (2) KR102227592B1 (es)
CN (2) CN105026373B (es)
AP (1) AP2015008633A0 (es)
AR (1) AR094667A1 (es)
AU (3) AU2014212509B2 (es)
BR (1) BR112015018289A2 (es)
CA (1) CA2898866C (es)
CL (1) CL2015002147A1 (es)
CY (1) CY1119163T1 (es)
DK (2) DK2953931T3 (es)
ES (2) ES2626555T3 (es)
GE (2) GEP20217286B (es)
HK (2) HK1217693A1 (es)
HR (2) HRP20170787T1 (es)
HU (2) HUE033370T2 (es)
IL (1) IL240195B (es)
LT (2) LT2953931T (es)
MX (2) MX2021003687A (es)
NZ (2) NZ750187A (es)
PE (2) PE20191495A1 (es)
PH (1) PH12015501661B1 (es)
PL (2) PL3239134T3 (es)
PT (2) PT3239134T (es)
RS (2) RS61503B1 (es)
RU (1) RU2662223C2 (es)
SG (2) SG11201505953TA (es)
SI (2) SI2953931T1 (es)
TW (2) TWI655187B (es)
UA (1) UA120589C2 (es)
UY (1) UY35288A (es)
WO (1) WO2014120808A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
KR102215620B1 (ko) 2013-07-19 2021-02-16 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 설폰아미드
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3459958A1 (en) 2013-12-13 2019-03-27 Vertex Pharmaceuticals Incorporated Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN107835805A (zh) 2015-05-22 2018-03-23 基因泰克公司 被取代的苯甲酰胺和其使用方法
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2017058821A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP2019508496A (ja) 2016-02-15 2019-03-28 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのｔａｆ１阻害剤
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
US11358977B2 (en) * 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
AU2019218387A1 (en) 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain
CN112041313A (zh) 2018-02-26 2020-12-04 基因泰克公司 吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
CR20210209A (es) 2018-11-02 2021-05-20 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inhibidores de
TW202039443A (zh) * 2019-01-04 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧基－１，６－二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
TW202043200A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2020169042A1 (zh) * 2019-02-20 2020-08-27 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CA3150400A1 (en) * 2019-09-12 2021-03-18 Shanghai Jemincare Pharmaceuticals Co., Ltd PYRIDINE OXYNITRIDE, METHOD FOR PREPARATION AND USE
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
CN113045487A (zh) * 2019-12-27 2021-06-29 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CA3182633A1 (en) 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
KR20240005878A (ko) 2021-05-07 2024-01-12 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 시클로알킬 3-옥소피페라진 카르복스아미드 및 시클로헤테로알킬 3-옥소피페라진 카르복스아미드
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2023160509A1 (zh) * 2022-02-25 2023-08-31 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
CN116947713A (zh) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 并环类化合物及其应用
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (es) 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
EP1663979B1 (en) * 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CA2574600C (en) 2004-07-23 2010-08-31 Pfizer Inc. Pyridine derivatives
CN101238109B (zh) 2005-06-09 2011-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的茚满衍生物
US7855220B2 (en) 2005-09-09 2010-12-21 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
CA2624831A1 (en) 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
CN101466665B (zh) * 2006-04-11 2013-12-04 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
ES2398606T3 (es) * 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
US8193194B2 (en) 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
AU2008310660A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118467A (ru) * 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
CA2701766A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
US8461185B2 (en) * 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
EP2382202A1 (en) 2008-12-23 2011-11-02 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
JP5685203B2 (ja) * 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
CA2825204C (en) 2011-02-02 2019-06-11 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
CN103561723B (zh) 2011-03-29 2016-04-20 赛诺菲 具有改善稳定性的奥米沙班制剂
WO2013021535A1 (ja) 2011-08-10 2013-02-14 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
MD4590C1 (ro) 2012-03-06 2019-03-31 Pfizer Inc. Derivaţi macrociclici pentru tratamentul bolilor proliferative
CN102659628B (zh) 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
SG11201505954RA (en) 2013-01-31 2015-08-28 Vertex Pharma Amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
KR102215620B1 (ko) 2013-07-19 2021-02-16 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 설폰아미드
EP3459958A1 (en) 2013-12-13 2019-03-27 Vertex Pharmaceuticals Incorporated Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
AU2019218387A1 (en) 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain

Also Published As

Publication number Publication date
EP3239134A1 (en) 2017-11-01
LT3239134T (lt) 2021-02-25
EP2953931B1 (en) 2017-03-01
JP6741704B2 (ja) 2020-08-19
AP2015008633A0 (en) 2015-07-31
RU2018126184A (ru) 2019-03-12
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
US10738009B2 (en) 2020-08-11
JP2016506963A (ja) 2016-03-07
TWI655187B (zh) 2019-04-01
KR20210029848A (ko) 2021-03-16
JP6389194B2 (ja) 2018-09-12
US20210047271A1 (en) 2021-02-18
AU2018214105B2 (en) 2020-04-02
SG11201505953TA (en) 2015-08-28
IL240195A0 (en) 2015-09-24
TW201943701A (zh) 2019-11-16
GEAP201414909A (es) 2020-07-10
RU2662223C2 (ru) 2018-07-25
US9758483B2 (en) 2017-09-12
PH12015501661A1 (en) 2015-10-19
HRP20170787T1 (hr) 2017-08-11
BR112015018289A2 (pt) 2017-07-18
WO2014120808A1 (en) 2014-08-07
CN108164457B (zh) 2021-07-09
TW201443019A (zh) 2014-11-16
US9393235B2 (en) 2016-07-19
HUE053448T2 (hu) 2021-06-28
CN108164457A (zh) 2018-06-15
SI2953931T1 (sl) 2017-08-31
KR102295748B1 (ko) 2021-09-01
PH12015501661B1 (en) 2015-10-19
HK1244269A1 (zh) 2018-08-03
AU2014212509B2 (en) 2018-05-10
US20140213616A1 (en) 2014-07-31
CN105026373B (zh) 2018-03-30
RS56015B1 (sr) 2017-09-29
WO2014120808A8 (en) 2015-09-11
UA120589C2 (uk) 2020-01-10
LT2953931T (lt) 2017-07-25
US10087143B2 (en) 2018-10-02
CY1119163T1 (el) 2018-02-14
KR20150112031A (ko) 2015-10-06
MX2015009602A (es) 2015-11-25
EP3865475A1 (en) 2021-08-18
RU2018126184A3 (es) 2021-07-26
CA2898866C (en) 2023-03-07
HRP20210349T1 (hr) 2021-04-16
CN105026373A (zh) 2015-11-04
PE20191495A1 (es) 2019-10-21
HK1217693A1 (zh) 2017-01-20
JP2021001232A (ja) 2021-01-07
KR102227592B1 (ko) 2021-03-15
RU2015136795A (ru) 2017-03-10
US20190248745A1 (en) 2019-08-15
US20170037009A1 (en) 2017-02-09
PL3239134T3 (pl) 2021-06-14
PT2953931T (pt) 2017-06-14
WO2014120808A9 (en) 2015-05-14
DK3239134T3 (da) 2021-02-22
PT3239134T (pt) 2021-01-28
AU2018214105B9 (en) 2020-04-23
JP2019089861A (ja) 2019-06-13
CL2015002147A1 (es) 2016-06-03
TWI714967B (zh) 2021-01-01
US20180016235A1 (en) 2018-01-18
JP2018104453A (ja) 2018-07-05
AU2020204425A1 (en) 2020-07-23
EP3239134B1 (en) 2020-12-23
US9051270B2 (en) 2015-06-09
SG10201706206PA (en) 2017-08-30
MX2021003687A (es) 2023-01-25
AR094667A1 (es) 2015-08-19
DK2953931T3 (en) 2017-06-06
HUE033370T2 (en) 2017-11-28
EP2953931A1 (en) 2015-12-16
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
AU2018214105A1 (en) 2018-08-30
PE20151781A1 (es) 2015-12-02
NZ710270A (en) 2020-09-25
IL240195B (en) 2019-10-31
ES2857687T3 (es) 2021-09-29
GEP20207177B (en) 2020-11-10
AU2014212509A1 (en) 2015-08-06
GEP20217286B (en) 2021-08-25
SI3239134T1 (sl) 2021-03-31
US20150246028A1 (en) 2015-09-03
ES2626555T3 (es) 2017-07-25
CA2898866A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
UY35288A (es) Piridonamidas como moduladores de canales de sodio
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CO2019013021A2 (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
MX359882B (es) Amidas como moduladores de canales de sodio.
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CL2015002188A1 (es) Agentes analgésicos oculares tópicos
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
CL2012001818A1 (es) Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20221209